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Abstract
Driving with alcohol and other psychoactive substances imposes an increased risk of severe injury
accidents. In a population-based case-control design, the relative risks of severe driver injury (MAIS ≥ 2)  by 
driving with ten substance groups were approximated by odds ratios (alcohol, amphetamines, 
benzoylecgonine, cocaine, cannabis, illicit opiates, benzodiazepines and Z-drugs, i.e. zolpidem and 
zopiclone, medicinal opioids, alcohol-drug combinations and drug-drug combinations). Data from six 
countries were included in the study: Belgium, Denmark, Finland, Italy, Lithuania and the Netherlands. Case 
samples (N=2,490) were collected from severely injured drivers of passenger cars or vans in selected 
hospitals in various regions of the countries. Control samples (N=15,832) were sampled in a uniform 
sampling scheme stratified according to country, time, road type and season. Relative risks were 
approximated by odds ratios and calculated by logistic regression. The estimates were adjusted for age, 
gender and country. 
The highest risk of the driver being severely injured was associated with driving positive for high 
concentrations of alcohol (≥ 0.8 g/L), alone or in combination with other psychoactive substances. For 
alcohol, risk increased exponentially with blood alcohol concentration (BAC).  The second most risky 
category contained various drug-drug combinations, amphetamines and medicinal opioids. Medium 
increased risk was associated with medium sized BACs (at or above 0.5 g/L, below 0.8 g/L) and
benzoylecgonine. The least risky drug seemed to be cannabis and benzodiazepines and Z-drugs. 
For male drivers, the risk of being severely injured by driving with any of the psychoactive substances was 
about 65% of that of female drivers. For each of the substance groups there was a decrease in the risk of 
severe driver injury with increasing age.
It is concluded that among psychoactive substances alcohol still poses the largest problem in terms of 
driver risk of getting injured.
Keywords:  driving under the influence, driver injury risk, road accident, case-control design
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1. Introduction
It is estimated that alcohol is responsible for 25% of the annual road fatalities in Europe, and that at least 
10,000 people are killed in alcohol-related road accidents in the EU each year (Commission of the European 
Communities, 2006, SafetyNet, 2009). An equivalent estimate for drugs has not been published, but the 
incidence of drugs among drivers injured or killed in road accidents has been studied, and this incidence has 
been reported to fall in the range of 14% to 17% (OECD, 2010), well above the prevalence of drugs among 
drivers in general (OECD, 2010). This does not necessarily mean that drugs are responsible for all these 
accidents, but it is an indication that there is a relation between the two.
Driving when positive for alcohol affects driving performance (driving skills) and driving behaviour. In two 
publications, Moskowitz and Robinson (1987) and Moskowitz and Fiorentino (2000) systematically 
reviewed papers analysing the effect of Blood Alcohol Concentration (BAC) on driving performance (driving 
skills). Moskowitz and Robinson (1987) summarized 177 studies and concluded that ‘…there appears no 
lower BAC below which impairment cannot be said to exist.’ In a similar set up, Moskowitz and Fiorentino 
(2000) reviewed 112 papers and concluded that impairment begins with any departure from zero BAC, and 
by 0.5 g/L the majority of studies report impairment. Krüger (1993) in his review concluded that social and 
controlled behaviours (involving a greater mental workload) are impaired at the lowest BAC (0.30-0.49 g/L) 
whereas automatic behaviours (involving less mental workload) are not impaired until 0.5 g/L. Evans (2004) 
studied driving behaviour after alcohol intake and concluded that at a BAC of 0.5 g/L judgement is altered, 
and the person is less inhibited.  
Whereas the above studies treat the effect of alcohol on single human factors separately, an 
epidemiological study is designed to assess the overall increased risk of getting involved in an 
accident/getting injured or killed when driving positive for alcohol. By far the most cited of the studies is 
the Grand Rapids study by Borkenstein et al. (1974).  
The fitness to drive while positive for psychoactive stimulants is not entirely clear: a meta-analysis of 
experimental studies of the effect of therapeutic doses of amphetamines and cocaine (that have 
stimulating effect on mental and physical performance (OECD, 2010)) found no negative effects on the 
fitness to drive (Berghaus et al., 2011); yet in an epidemiological study from Norway, the odds ratio of 
getting killed or severely injured when positive for amphetamines was 47.8 (Assum et al., 2005), thus very 
far from being harmless.  In a recent meta-analysis on the relative risk of injury accidents associated with 
the use of drugs, Elvik (2012) found insignificant effects of the use of benzodiazepines, cannabis, cocaine 
and zopiclone, whereas the use of amphetamine and opiates was associated with significantly elevated 
risks (odds ratios of 6.19 and 1.89, respectively).
The purpose of the present study was to assess the overall driver risk of being severely injured by driving 
with alcohol and/or other psychoactive substances. Psychoactive substances suspected to influence driving 
the most were included in the study (Simonsen et al., 2013). Benzodiazepines, Z-drugs and opioids make up 
most of the psychoactive medicines suspected to influence driving; thus several benzodiazepines, zolpidem, 
zopiclone, codeine, methadone and tramadol were included in the group of medicinal drugs while illicit 
drugs consisted of morphine (heroin), amphetamines, cocaine and cannabis.  Data were collected in six 
countries in different parts of Europe according to the same protocol. This study has enough data to assess 
injury risk for less prevalent psychoactive substances as well as for the combination of alcohol and other 
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psychoactive substances. Moreover, data allow assessing relations between severe driver injury risk and 
driving while positive for different concentrations of alcohol.
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2. Methodology
2.1 Data collection
The driver risk of being severely injured by driving with psychoactive substances was assessed in a 
population-based case-control design in six countries: Belgium (BE), Denmark (DK), Finland (FI), Italy (IT), 
Lithuania (LT) and the Netherlands (NL). The case sample consisted of blood specimens from drivers of 
passenger cars or vans (up to 3,500 kg) who were severely injured (MAIS≥2 or equivalent, cf. Hels et al. 
(2011)). The MAIS scale runs from 1-6, with a score of 1 indicating minor injury in road accidents and 6 
indicating death with four in-between stages: moderate, severe, serious and critical injury (Garthe et al.,
1999). The control sample consisted of specimens of oral fluid/blood from drivers of passenger cars or vans 
who were stopped randomly on main urban and rural roads at selected sites and times (N=15,832). In Table 
1 the distribution of samples over the participating countries is shown. Case samples (N=2,490) consisted of 
blood samples from all severely injured car/van drivers in trauma centre(s) of selected hospitals in various 
regions of the country. Information on the driver was collected (age and gender), and a blood sample was 
taken for subsequent toxicological analysis. Control samples were collected in the catchment areas of the 
trauma centre(s) where case samples were collected. Case and control sample regions are shown in Table 
1.
< TABLE 1 HERE >
In a population case control design, cases and controls need to match on a population level. Along this line 
two questions were asked: 
1. In the case that a country had a higher number of road side survey regions (RSSR) than hospital 
survey regions (HSR) – true for DK, FI, IT and NL – it was tested (χ2-tests) if age and gender 
distributions of the sampled drivers were significantly different in the RSSR that were matched by a 
HSR and the RSSR that were not matched by a HSR. The results of these tests are presented in 
Table 2. If either age, gender or both distributions differed significantly, the RSSRs that were not 
matched by HSRs were not included in the risk calculations. If distributions did not differ, data from 
the unmatched RSSRs were included. 
2. In the case that a country had one or more HSR(s) that extended geographically beyond the RSSR(s)
– true for DK – it was tested (χ2-tests) whether there was a significant difference between the injury 
score distribution of the sampled injured driving population inside and outside of the RSSR(s). The 
results of these tests are presented in Table 3. This answers the question if the injured sampled 
population inside and outside of the road side survey area was injured to the same degree. 
<TABLE 2 HERE>
<TABLE 3 HERE>
Control samples were collected in a systematic way, covering a variety of research locations as well as all 
times of the day, week and year (Table 4). It was the intention that the survey sample should be 
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representative of traffic on all roads at all times. To this aim, eight sample periods covering the whole week 
were defined. In all countries, the controls were sampled over all eight time periods and subsequently, the 
data for each driver in the road side sample were weighted by the traffic fraction of the general driving 
population in the specific time period and country where the driver was stopped as recommended by 
Mathijssen and Houwing (2005). This way, data were weighted to represent general traffic. For actual 
weighting factors in different countries and time periods, we refer to Hels et al. (2011). 
<TABLE 4 HERE>
Drivers were tested for alcohol and drugs in a uniform way. For more information on the sampling 
procedure of controls, we refer to Houwing et al. (2011).  Collection of control samples was carried out in 
2008-2009 (BE, DK, IT, LT) and 2007-2009 (FI, NL). Collection of case samples was carried out in 2008-2010 
(BE, FI, LT, NL), 2007-2010 (DK) and 2008-2009 (IT).
Following legal regulations, participation in the alcohol breath test at the roadside was mandatory, whereas 
the drug test (sample of oral fluid and/or blood) was voluntary. This leads to a question of potential non-
response bias of control samples (Berghaus et al., 2007). Non-response bias occurs in the case that drivers 
who refuse to give a sample differ from those who do not with regard to drug use. Non-response in each 
participating country is shown in Table 5. Data were analysed for differences between respondents and 
non-respondents. In the Belgian data set (non-response rate (NRR): 52%), there was no significant 
difference in BAC for respondents and non-respondents which indicates no serious non-response bias (Van 
der Linden et al., 2011). In the Finnish data set (NRR: 48%) most of the non-respondents refused to 
participate when asked by the police. At this stage (before meeting the research team) they were not 
informed about the purpose of the study, only that it would take ten minutes. Thus, if the non-respondents 
were driving under the influence and afraid of being detected, they did not know the purpose of the study 
when refusing to participate. Moreover, the demographic profile of the respondents in the road side study 
was representative of the general Finnish driving population as described in a recently conducted study on 
the Finnish traffic distribution (Engblom et al., 2011; Ministry of Transport and Communications Finland). In 
the Lithuanian data set, NRR added up to 24%. In Lithuania all the refusers were aged 18-31 and two thirds 
were women. This may indicate non-response bias, but all refusers were checked for signs of impairment, 
and none of them showed any (Caplinskiene et al., 2011). In Denmark, NRR was 5%. There was no 
difference in gender and age between the respondents and the non-respondents (Hels et al., 2011). In the 
Netherlands (NRR: 5%) male and younger drivers were overrepresented among the non-respondents. 
There was no difference in distribution of BAC levels between the respondents and the non-respondents 
which is an indication of no non-response bias. On the other hand, the self-reported use of psychoactive 
substances was higher for the non-response group (6.5%) than for the response group (3.6%) which 
indicates the probability of a non-response bias (Houwing et al., 2011). In Italy, the NRR was 0% because of 
a legal regulation that allows mandatory body fluid collection by a physician assisted by a police officer 
(Ferrara et al., 2011). If drivers positive for psychoactive substances were more likely to refuse participation 
in the road side survey than others, this would lead to an overestimation of risk.
<TABLE 5 HERE>
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In Finland, the police allowed only an unknown fraction of the alcohol positives to be sampled, and in Italy, 
there was skewness in the driving population sampled towards drivers exhibiting signs of alcohol 
impairment. Consequently, negative samples and samples positive for alcohol or alcohol-drugs from these 
two countries were excluded from the calculations of OR for alcohol and alcohol-drugs.
Inclusion of the case drivers in the study was supposed to be done regardless of a suspicion of them being 
positive for psychoactive substances. In practice, there may have been sampling bias with patients more 
likely to be positive for psychoactive substances included more readily. If this were the case, it would result 
in an overestimation of risk. Another source of risk overestimation would be lack of information on any 
drugs administered after the accident but before the blood sample was taken (particularly medicinal 
opioids for pain relieving). It is not possible to estimate the size of a potential over- or underestimation of 
risk. 
2.2 Toxicological analysis
As indicated, oral fluid and/or blood samples were collected at the road side (controls) and blood was 
sampled in the hospitals (cases). Blood samples were treated as follows:
 5-10 mL whole blood collected in vacuum tubes containing sodium fluoride and potassium oxalate
 Transported at 4°C (max. 48h)
 Stored in laboratory at -20°C
The criteria for oral fluid samples were:
 1 mL oral fluid sampled using StatSure SalivaSamplerTM (StatSure Diagnostic Systems, Framingham, 
MA, USA)
 Sampled according to guidelines by manufacturer
 Transported at 2-8°C (max. 48h)
 Stored in laboratory at -20°C
An exception occurred in The Netherlands where the drivers spitted in a cup. However, it was shown 
(Langel et al., 2008) that the concentrations in oral fluid analysed by means of pure saliva (The Netherlands) 
did not differ from the concentrations analysed by means of the oral fluid from the StatSure 
SalivaSamplersTM that were diluted by the buffer in the sampler.
The StatSure SalivaSamplerTM device was chosen among nine different oral fluid collection devices 
evaluated for the recovery and stability of drugs and suitability of the device for sample collection (Langel 
et al. 2008). As part of the project, new analysis methods were developed that enabled a simultaneous 
quantitation of a large number of substances from a small sample volume (Badawi et al., 2009; Langel et 
al., 2011).
All blood- and oral fluid samples were analysed by means of fully validated methods for the same number 
of substances in all countries. Proficiency test analyses of oral fluid and whole blood were carried out by all 
participating laboratories, resulting in a high quality of toxicological analyses in all countries. For more 
detailed descriptions of the toxicological procedures, cf. Badawi et al. (2009), Isalberti et al. (2011), and 
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Langel et al. (2011). If both a blood and an oral fluid sample were taken, the toxicological analysis of the 
blood sample was used. 
The following psychoactive substances were included in the analyses: alcohol, stimulants (amphetamines, 
cocaine), cannabis, narcotic analgesic (illicit opiates), sedatives (benzodiazepines, Z-drugs), narcotic 
analgesic (medicinal opioids). In total, 24 substances were analysed for in each participating country. The 
analytical findings were evaluated according to Table 6. The groups were mutually exclusive. A sample 
positive for alcohol and cannabis was considered positive for alcohol-drugs but negative for both alcohol 
and cannabis. A sample positive for more substances within the same group (e.g. oxazepam and lorazepam) 
was not considered positive for multiple drugs, but for the substance group (in casu benzodiazepines) only. 
Samples categorised as negative were negative (i.e. below cut-off) for each of the tested substances. 
In the body, cocaine metabolises to benzoylecgonine that is pharmacologically inactive. Nevertheless, 
benzoylecgonine was identified and interpreted as a sign of recent cocaine use. 
< TABLE 6 HERE >
Determining whether a subject was positive for a substance or not, was done by toxicological analyses of 
samples from both blood and oral fluid. Thus, to compare the saliva-positive subjects with the blood-
positive subjects it was crucial that equivalent cut-offs for blood and oral fluid were developed. These 
equivalent concentrations were developed by Verstraete et al. (2011) on the basis of samples from 
countries in which both blood and oral fluid was collected. The existence of equivalent concentrations
partly solves the problem of comparing results based on two different specimens collected. The following 
results are based on concentrations of the substances in question that are equal to or exceed the above-
mentioned equivalent concentrations in blood and in oral fluid. For the exact values of the equivalent cut-
offs, we refer to Verstraete et al. (2011). The equivalent cut-offs should be used with caution because in 
some cases they were determined from few studies (MDA, MDMA, 6-AM, and zopiclone) and no equivalent 
cut-off was determined for MDEA, therefore, the MDMA factor was used. 
2.3 Statistical analysis
Under certain assumptions, relative risk (RR) can be approximated by odds ratio (OR) (Schmidt and 
Kohlmann, 2008). The assumptions are: 1) a low probability of severe driver injury among the drivers 
negative for all psychoactive substances (lower than 10%, ‘the rare disease assumption’), 2) a relatively low 
OR (about 4). In this study, relative risk of severe driver injury by driving with psychoactive substances was 
approximated by the OR, i.e. the driver odds of being severely injured by driving with one or more 
psychoactive substances relative to the driver odds of being severely injured by driving with no 
psychoactive substances (Hels et al., 2011). This approximation is further discussed in the discussion 
section.
OR’s were calculated with logistic regression (Proc logistic, SAS 9.2). Logistic regression relates a number of 
independent variables to the probability of an event, in this case the driver probability of being severely 
injured by driving with psychoactive substances. 
The logistic function is given by
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(1)
Here, P(y) denotes the driver probability of being severely injured by driving with psychoactive substances. 
The logit, y, is a linear expression of x
(2)
where  denote the four independent variables age group, gender, 
presence of a substance, and country, respectively (Table 7), and the β’s are the parameters estimated in 
the logistic regression. The four independent variables are all categorical. 
By rearranging, the formula (1) can be put on the form of an odd
(3)
Using (2), the odds ratio for severe driver injury given presence of substance can then be expressed as
(4)
In a similar fashion, the odds ratios can be computed for severe driver injury given other independent 
variables.
The odds ratios have been calculated by means of logistic regression for the following substance groups: 
Alcohol, amphetamines, benzoylecgonine, cocaine, cannabis, illicit opiates, benzodiazepines and Z-
drugs, as well as medicinal opioids. Two extra groups, alcohol-drugs and multiple drugs, were included.
Negative samples, that is samples for which no substances have been found in concentrations above or 
equal to the equivalent cut-off, made up the reference group irrespective of the substance group in 
question. The description of all modelling variables can be found in Table 7. Alcohol and/or other 
psychoactive substances represent the dependent variables – the presence of which is modelled by logistic 
regression. Age, gender and country are variables adjusted for in the model. Adjusting for variables in the 
model corresponds to keeping them constant, thus creating an everything-else-being-equal-scenario. For 
example, when adjusting for age, the effect of the drug on the probability of severe driver injury is isolated
from the effect of age on injury probability. This gives comparable risk estimates for the various drugs.
< TABLE 7 HERE>
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3. Results
Estimated driver odds ratios for being severely injured by driving with various psychoactive substance 
groups are shown in Table 8 and Figure 1. The estimated odds ratios are based on data from all six 
countries.
< TABLE 8 HERE>
The most striking feature of Figure 1 and Table 8 is the exponential risk increase with the driver’s increasing 
blood alcohol concentration. The adjusted odds ratio of a BAC of 0.1-0.49 g/L was 1.3 and not significantly 
different from 1, whereas all BACs at or above 0.5 were associated with significant increases in risk relative 
to driving sober. The risk of driving with the highest BAC (at or above 1.2 g/L) was as high as 78 times higher 
than driving sober. The risks associated with driving with high BACs (at or above 0.8 g/L) were significantly 
higher than the risks of driving with illicit drugs (taken as one group) and medicinal drugs (taken as one 
group). The risk of severe driver injury by driving with a combination of alcohol and (any) other drug(s) was 
quite high, namely about 39 times higher than driving negative for all substances.  This risk, too, was 
significantly higher than driving with the recorded illicit or medicinal drugs.
Among the illicit drugs amphetamine stood out as being associated with a higher risk than the other drugs, 
even though the confidence interval of the odds ratio is quite wide (Table 8). Cocaine and illicit opiates 
were associated with similar risks not significantly elevated, whereas cannabis was associated with a 
slightly elevated risk and benzoylecgonine with a somewhat higher risk.
Driving with medicinal opioids was associated with a significantly higher risk of severe driver injury than the 
substance group benzodiazepines and Z-drugs, i.e. 7.4 and 1.8, respectively – both however being 
significantly higher than 1. Generally, the risks associated with driving with illicit drugs and medicinal drugs 
(taken as groups) were of similar magnitude with amphetamine and medicinal opioids standing out as 
exceptions associated with higher risks. Driving with various combinations of drugs was found to be 
significantly more risky than driving negative, but significantly less risky than driving with a combination of 
alcohol and other drugs. 
< TABLE 9 HERE>
When adjusted for national differences in odds ratios, gender related odds ratios were similar across the 
various substances (Table 9). For male drivers, the risk of being severely injured by driving with 
psychoactive substances was about 65% of that of female drivers. For each of the substance groups, this 
difference was highly significant. For each of the substance groups there was a decrease in the risk of 
severe driver injury with increasing age, but to different extents: The largest difference was for drivers 
positive for alcohol or a combination of alcohol and drugs. In these cases, driving with alcohol was more 
than five times more risky for young drivers (18-24 years old) than for older drivers (50+). The risk gradually 
decreased with age. For drivers aged 35-49 the risk was still significantly higher than the risk for those aged 
50+. For all other psychoactive substance groups the pattern was similar: the risk of severe driver injury by 
driving with the drug was about three times as high for the young drivers (18-24) than for the drivers aged 
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50+. With increasing age this risk decreased, and for the drivers aged 35-49, the risk was not significantly 
different from that of the drivers aged 50+. 
< FIGURE 1 HERE >
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4. Discussion
An epidemiological study design reveals overall manifestations of risk factors, and this design is useful in 
assessing the role of risk factors in a large population (Berghaus et al., 2007). Case-control studies of drink 
and drug driving assess the risk in interaction with confounding factors such as risk taking behaviour, 
driving style, driving experience, fatigue, weather, road condition and choice of vehicle. Moreover, the 
dosage of alcohol/drug is not under the control of the researcher, but represents real life 
recreational/medical use. Case-control studies thus provide us with real life risks but with limited possibility 
to isolate the different confounding effects and control the dosage. To partly overcome the confounding 
effects, we have adjusted the risk estimates for age, gender and country, the first two to some extent being 
proxies for driving style. For all psychoactive substances analysed the estimated risk was higher for young 
drivers, lower for adult drivers and even lower for older drivers. Moreover, the estimated risk was lower for 
male than for female drivers. This modelling result is a combination of potentially different physiological 
effects of the drugs according to age and gender, age- and gender related vulnerability and a difference in 
driving style, risk willingness, vehicle choice and other factors proxied by age and gender.
The higher risk for young drivers of being severely injured compared to older drivers is not physiologically 
substantiated. Rather, it is probably founded in younger drivers’ higher risk willingness when driving. The 
higher risk for female than male drivers seems paradoxical because female drivers are known to be less 
willing to take risk than male drivers (Evans, 2004), and this would logically lead to fewer female than male 
drivers being severely injured even when positive for psychoactive substances. There are, however, a 
number of possible reasons for this result: First, women have a smaller body volume to distribute any 
concentration of psychoactive substance than men do, and female drivers thus get more affected by a 
given substance amount. Second, it is well known that women are physically more vulnerable than men 
and suffer more severe injury at the same impact than men do (Evans, 2004). Thus, some of the accidents 
that resulted in severe injury for female drivers may have resulted in light or no injury for male drivers and 
consequently the accidents have not been included in the study. Third, women tend to drive smaller cars 
with less protection than men (Elvik and Vaa, 2004) which generally results in more severe injuries.
Odds ratios are always overestimations of relative risk, but using odds ratios gives the possibility of 
adjusting for confounding variables such as age, gender and country. Relative risk is most accurately
approximated by odds ratio for low probabilities of severe driver injury among the drivers negative for all 
psychoactive substances (Schmidt and Kohlmann, 2008) and for small values of odds ratios. In this study, 
the relation between severely injured drivers and all drivers negative for psychoactive substances equals 
(1177)/(1177+11073) = 9.6% (Table 8). This is close to the maximum 10% recommended by Schmidt and 
Kohlman and means that for example an RR of 3 is approximated by an OR of 4, and an RR of 5 is 
approximated by an OR of 9.
The size of the risk estimates when driving positive for alcohol is a confirmation of the fact that alcohol is 
still the major road safety problem drug in terms of injury risk. The exponential increase in risk with 
increasing BAC found in this study complies with that of Borkenstein (1974), and the risk estimates fall in 
line with those of other epidemiological studies (Assum et al., 2005; Borkenstein, 1974; Hurst et al., 1994;
Woratanarat et al., 2009). The high risk estimates of higher alcohol concentrations (at or above 0.8 g/L) 
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compared to (most) drugs and medicine is difficult to explain. It may originate in one or a combination of 
the following: Physiological effects being different for various psychoactive substances with alcohol 
impairing safe driving more than the other substances; the psychoactive substances having been taken in 
different concentration equivalents and finally the fact that medicinal drugs presumably have been taken to 
remedy a medical condition that may in itself compromise safe driving. Following this logic, alcohol and 
other drugs taken for recreational purposes (amphetamines, cannabis, cocain and illicit opiates) would be 
associated with higher driver injury risk than medicinal drugs. This is true for alcohol and amphetamine, but 
not for the other illicit drugs and medicinal opioids. Controlled experiments are called for to assess dose-
response functions of intake of various drugs and medicines and the degree of compromise of safe driving. 
For example, Schnabel et al. (2010) conducted a meta-analysis of empirical studies of the effects of alcohol 
on safe driving, and their conclusion was that alcohol impairment functions are linear, while risk functions 
are exponential. Their explanation was that driving is a combination of subtasks that each may have a 
different impairment function, and that the result is a weighted aggregation of task-specific impairment 
functions.
Among the illicit drugs, amphetamine stood out as being associated with significantly higher driver injury 
risk than the others. In the literature, experimental results on driving with amphetamines indicate increase 
in driving performance (Gustavsen et al., 2006; Ramaekers, 2011). This is logical, since therapeutic doses of 
stimulants produce intense excitement and euphoria as well as alertness together with a decrease in 
reaction time (OECD, 2010) – effects that may improve psychomotor skills to a certain extent (Gustavsen et 
al., 2006). In real life settings, however, doses may be much higher than therapeutical, a situation that 
would be unethical to mimic in an experimental setting. Gustavsen et al. (2006) tested real-life 
amphetamine users and found a positive relationship between blood amphetamines concentration 
(BAmphC) and (police assessed) driving impairment. They found significantly increased impairment above 
BAmphCs of 270 ng/mL. 
In the present study, out of 17 control drivers exclusively positive for amphetamines (not in combination 
with alcohol or other drugs), only 7 gave a blood sample (the others gave an oral fluid sample). For these 7 
drivers, the median BAmphC was 144, and only 2 out of the 7 had BAmphCs exceeding 270 ng/mL, whereas 
5 out of the 7 had BAmphCs above that of therapeutic doses which would typically be up to 100 ng/mL 
(Hargutt et al., 2011). Out of 15 accident involved drivers exclusively positive for amphetamines the median 
BAmphC was 140 ng/mL, and only 3 out of 15 drivers’ BAmphCs exceeded 270 ng/mL. Yet, 8 out of 15 
drivers’ BAmphC exceeded that of therapeutic doses. This material is numerically small but does not 
unambiguously support the hypothesis of far higher dosages in real life settings than in experiments. More 
likely, the higher risk in real life settings may be due to interaction between the substance and the risk 
taking behaviour so that users of amphetamines had a high affinity to risky situations – partly because they 
were under influence of the drug and partly because drivers who take amphetamines per se have a high 
risk affinity. Finally, the increased risk may be due to sleep deprivation after long waking periods induced by 
the amphetamines (Hargutt et al., 2011; OECD, 2010). 
In the present study, the driver risk of being severely injured associated with driving with cocaine and illicit 
opiates was lower than the ones estimated by Dussault et al. (2002). However, in Dussault et al. (2002) the 
estimates were not adjusted for age and gender, and their case group consisted of killed drivers. 
Unadjusted cocaine risk estimates from this study complied well with the one in Dussault et al. (2002), but 
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the illicit opiate risk estimate in this study was significantly above one which was not the case in Dussault et 
al. (2002). Movig et al. (2004) adjusted for age and gender, and their estimates are not significantly higher 
than one and thus comparable to the ones in this study. Thus, driving positive for illicit opiates and cocaine 
may be associated with an elevated risk for some drivers (young and adult drivers, female drivers), but with 
all drivers as one group the risk is not significantly higher than one. The higher odds ratio of 
benzoylecgonine compared to its parent compound, cocaine, may be caused by cocaine rapidly 
disappearing from the blood but still exerting an effect on driving performance (Simonsen et al., 2013).The 
driver injury risk estimated with driving positive for cannabis was just above one and complies well with 
several other studies where the risk varies from just around and not significantly different from one to 
around 3 (OECD, 2010). Medicinal opioids were associated with higher odds ratios than illicit opiates. This 
seems strange as the pharmacological profile is rather close for these two groups. This can possibly be 
explained by the few positive illicit opiate cases in both the case and control groups which makes the 
calculation of odds ratio for illicit opiates less reliable.
The risk of being severely injured by driving with alcohol combined with another psychoactive substance 
was generally higher than the risk of driving with alcohol or other drugs alone. This is in accordance with 
the fact that alcohol and (most) drugs like opioids, benzodiazepines and Z-drugs with a CNS depressant 
effect have a synergetic, not an additive effect. However, Veldstra et al. (2011) found in an experiment that 
ecstasy partly compensated for the effect of alcohol on driving performance when both drugs were given in 
combination. The combined risk of alcohol and other drugs was higher than the risk of other drugs 
combined with other drugs. This finding is consistent with the finding of Assum et al. (2005). The risk of 
combined use should not be generalised since the combined use of alcohol and other drugs and drugs with 
other drugs represents many different combinations of drugs.
5.1 Strengths and limitations of the study
In case-control studies a high number of both cases and controls is a prerequisite for obtaining reliable risk 
estimates. One clear strength of this study is the high number of control and case samples. The samples are 
distributed on six European countries, and for all we know, this is the first study on risk related to drink and 
drug driving performed simultaneously in six countries using a common study design. In each participating 
country, the number of positive cases was below five for one or more substance groups. Pooling the data 
thus improved the quality of the risk estimates considerably. It is highly questionable whether data from 
this study form a representative basis for common European risk estimates as far from all European
countries participated in the study. However, it is fair to assume that the risk estimates represent the 
countries involved in this study.
This having been mentioned, there are drawbacks of the study as well: The high non-response rates in 
some countries may have affected the risk estimates. In the Methods section we have made it probable 
that among the controls there was no significant difference between the respondents and the non-
respondents, but even an insignificant difference may affect the exact value of the risk estimate. The non-
respondents in the control sample are likely to be positive for psychoactive substances, whereas in the case 
(hospital) sample, the hospital staff may be more likely to include patients believed to be positive. Thus, the 
non-respondents in both the control and the case sample may have led to the same direction – to an 
overestimation of risk. Our analyses suggest that the overestimation is of minor importance, and we 
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conclude that the exact risk estimates must be handled with caution whereas the orders of magnitude of 
risk estimates are reliable. 
In the study, not all existing opioids and benzodiazepines were analysed for, neither in the case nor in the 
control samples, so prevalence of these drugs are probably underestimated. As this is the case for both 
injured and control drivers, it is not possible to assess if it results in over- or underestimation of risk.
Collecting oral fluid at the road side has many advantages over blood and urine: it is fast, easy, non-
invasive, and there is a lower risk of infection than by sampling blood (Langel, 2011). These are all factors 
that probably have contributed to lowering the non-response rate. In the hospitals, it was most suitable to 
collect blood samples due to the physical condition of some of the patients. Comparing substance 
concentrations from different body specimens is non-trivial. In a study parallel to this one, conversion 
factors were developed particularly for StatSureTM oral fluid and blood cut-off concentrations (Verstraete et 
al., 2011). The conversion factors can only be used for epidemiological studies and not for individual cases 
because of large individual variations. As mentioned earlier the conversion factors should be used with 
caution because in some cases they were determined from few studies (MDA, MDMA, 6-MAM, and 
zopiclone) and no conversion factor was determined for MDEA, therefore, the MDMA factor was used.  
The equivalent cut-offs in blood and oral fluid are presented in Hels et al. (2011). Being able to convert cut-
off values from one specimen to another allowed us to keep a high response rate for case as well as control 
samples.
5. Conclusion
Based on the results of this study it can be concluded that the highest driver risk of being severely injured 
by driving with psychoactive substances is associated with driving with high concentrations of alcohol in the 
blood (≥ 0.8 g/L). Driving with high concentrations of alcohol in blood alone or in combination with other 
drugs was riskier than driving with any other drug. The second most risky category contained various drug-
drug combinations, amphetamine and medicinal opioids. Medium increased risk was associated with 
alcohol in blood concentrations at or above 0.5 g/L and below 0.8 g/L and benzoylecgonine. The least risky 
drugs were cannabis and benzodiazepines and Z-drugs. Drugs associated with no significant risk increase 
were alcohol below 0.5 g/L, cocaine and illicit opiates. 
Because of the sources of error, the main one being the non-response rate, the orders of magnitude of the 
risk estimates are reliable (e.g. alcohol all concentrations: 10, alcohol at or above 1.2 g/L: 80) whereas 
specific risk estimates (e.g. alcohol all concentrations: 9.79, alcohol at or above 1.2 g/L: 77.76) must be 
handled with caution. Due to the non-response biases described above the risks are probably slightly 
overestimated, but the orders of magnitude are reliable.
Even though this study included a large number of samples, risk estimates are associated with wide 
confidence intervals. A larger data set would allow for the estimation of more accurate risk estimates with 
narrower confidence intervals. Several research questions remain unsettled, particularly related to the risk 
of driving when positive for illegal opiates and medicinal opioids. 
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In this study we have adjusted the risk estimates for the confounding variables driver age, gender and 
country. However, the epidemiological study design does not allow for adjusting for all risk related 
confounding variables such as driver risk taking behaviour, driving style, driving experience, fatigue, 
weather, road condition and choice of vehicle. We recommend that our study be followed up by 
experiments on driving performance when the driver is positive for various concentrations of psychoactive 
substances. It would be of particular interest to analyse experimentally dose-response relations between
various psychoactive substances, driving performance, driver age and gender.
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Figure 1. Odds ratios (OR) with 95% CI for severe driver injury by driving with psychoactive substances. OR’s 
are adjusted for age, gender and country.
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Table 1 
The number of case and control samples and sampling regions in each participating country.
Country Cases Controls
N Specimen Sampling region N Specimen Sampling region
Belgium 348 Blood 1. Brussels
2. Flanders
3. Wallonia
2,949 Oral fluid only (199)/blood 
only (0)/both (2,750)
1. Brussels
2. Flanders
3. Wallonia
Denmark 839 Blood 1. Ålborg and 
Viborg
2. Kolding, Vejle 
and Odense
3,002 Oral fluid only 1. Ålborg and Viborg
2. Kolding, Vejle and 
Odense
3. Roskilde
Finland 54 Blood 1. Uusimaa 2,706 Oral fluid only 1. Uusimaa
2. Pohjois-Savo
Italy 676 Blood 1. Padova
2. Venezia
4. Treviso
5. Rovigo
1,086 Oral fluid only (294)/blood 
only (0)/both ( 792)
1. Padova
2. Venezia
3. Vicenza
4. Treviso
5. Rovigo
Lithuania 385 Blood 1. Vilnius
2. Kaunas
3. Klaipeda
4. Alytus
1,267 Blood only 1. Vilnius
2. Kaunas
3. Klaipeda
4. Alytus
The 
Nether-
lands
188 Blood 2. Tilburg (Tilburg 
hospital)
5. Twente 
(Enchede hospital 
only)
6. Gelderland-
Zuid (Nijmegen 
hospital only)
4,822 Oral fluid only (1,068)/blood 
only (3,476)/both(278)
1. Hollands-Midden
2. Tilburg
3. Amsterdam 
Amstelland
4. Groningen
5. Twente
6. Gelderland-Zuid
Total 2,4
90
Blood 15,832 Oral fluid only (7,269)/blood 
only (4,743)/both (3,820)
Page 22 of 31
Ac
ce
pte
d M
an
us
cri
pt
22
Table 2
Test for homogeneity in age and gender distribution in road side survey regions. 
Country Is there a significant different age- and gender distribution in the road side sample regions 
(RSSR) that are matched by hospital survey regions (HSR) and the road side sample regions 
that are not?
Denmark One RSSR out of the three, Roskilde, was not matched by an HSR.  
Roskilde (no. 3) was tested against the two other RSSRs: 1+2 (cf. Table 1) for differences in 
age- and gender distribution. No difference was found, neither in age (N=2,995, df=3, 
χ2=3.27, p=0.99) nor gender (N=2,998, df=1, χ2=0, p=1). Consequently, all data from the 
roadside survey were included in the relative risk calculations.
Finland One RSSR out of two, Pohjois-Savo, was not matched by an HSR.
Pohjois-Savo (no.2) was tested against the other (Uusimaa) for differences in age- and gender 
distribution. Significant differences were found, both in distributions of age (N=3,835, df=3, 
χ2=408.64, p<0.0001) and in gender (N=3,827, df=1, χ2=151.64, p<0.0001). Consequently, 
road side survey data from Pohjois-Savo were left out in the relative risk calculations.
Italy One RSSR out of five, Vicenza, was not matched by an HSR.
This one, Vicenza, was tested against the other four areas for differences in age- and gender 
distribution. Significant difference was found in gender distribution (N=1,310, df=1, χ2=73.25, 
p=0.007), but not in age distribution (N=1,310, df=3, χ2=20.12, p=0.57). Consequently, road 
side survey data from Vicenza region were left out in the relative risk calculations.
The 
Netherlands
Three RSSRs out of six (i.e. Hollands-Midden, Amsterdam Amstelland, Groningen) were not 
matched by an HSR. Thus, these three regions were tested against the regions 1+3+4, cf. 
Table 1 for differences in age- and gender distribution. No difference was found, neither in 
age (N=4,817, df=3, χ2=16.81, p=0.64) nor gender (N=4,817, df=1, χ2=12.45, p=0.26).
Consequently, all data from the roadside survey were included as controls in the relative risk 
calculations.
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Table 3
Test for homogeneity in injury severity distribution in hospital survey regions.
Country Is there a significant difference in distribution of injury severity score of the injured 
population within and outside of the road side survey region(s)?
Belgium HSRs matched RSSRs exactly by design. Consequently, all hospital study data were used in 
relative risk calculations.
Denmark HSR Kolding, Vejle and Odense (no. 2, cf. Table 1) extended beyond the corresponding RSSR. 
Trauma scores for all injured drivers in this region were grouped into four severity groups. 
Subsequently, the scores were tested for homogeneity within and outside the RSSR. No 
significant difference was found (N=530, df=3, χ2=7.03, p=0.07). Consequently, all hospital 
data were included in the relative risk calculations.
Finland Data from one of the RSSRs, Pohjois-Savo, were left out, cf. Table 2.
The HSR of the Uusimaa region matched RSSR exactly by design. Consequently, all hospital 
data from Uusimaa region were included in relative risk calculations. 
Italy Data from the fifth RSSR, Vicenza, were left out of the calculations, cf. Table 2.
The other HSR matched RSSR exactly by design (Padova and Rovigo regions), or RSSRs were 
larger than HSRs (Venezia and Treviso). Consequently, all hospital data from these four 
regions were included in relative risk calculations. 
Lithuania HSRs matched RSSRs exactly by design. Consequently, all hospital study data were included in 
relative risk calculations.
The 
Netherlands
In the Netherlands, three out of six RSSRs were matched by HSRs. In region no. 2, Tilburg, the 
HSR was larger than the RSSR; in region no. 5, Twente, the HSR and the RSSR matched each 
other quite well; and in region no. 6, Gelderland-Zuid, there was a certain overlap between 
the two. Since the regions were not defined precisely, homogeneity tests could not be 
carried out. Consequently, all hospital study data were used in relative risk calculations.
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Table 4
Time schedule for road side sampling.
        Weekdays         Weekend
1 Monday – Friday        04:00-09:59 5 Saturday and Sunday        04:00-09:59
2 Monday – Friday        10:00-15:59 6 Saturday and Sunday        10:00-15:59
3 Monday –Thursday    16:00-21:59 7 Friday – Sunday                 16:00-21:59
4 Monday – Thursday   22:00-23:59
uesday – Friday       00:00-03:59
8 Friday – Sunday                 22:00-23:59
Saturday – Monday            00:00-03:59
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Table 5
Non response percentage, cases and controls.
Country Non 
response 
percentage, 
drivers
(controls)
Non 
response 
percentage, 
injured 
drivers 
(cases)
Reasons for non-response, cases
Belgium 52% 5.4% For some drivers a patient form was filled in, but 
they refused to give a blood sample for 
toxicological analysis
Denmark 5% 5% Blood sample or patient sheet went missing
For some drivers a patient form was available but 
no blood sample; these drivers make up the non-
response percentage.
Finland 48% 8.5% No problems reported
Italy 0% 0% Accident information from the police could not be 
obtained
Lithuania 24% 0% No problems reported
The 
Netherlands
5% Unknown Drug and alcohol intoxicated patients were less 
likely to be blood sampled than sober patients
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Table 6
Grouping of substances included in the analysis.
Type Group Analytical findings
Alcohol Alcohol ethanol
Illicit Amphetamines amphetamine
Drugs methamphetamine or methamphetamine + amphetamine
MDMA* or MDMA + MDA**
MDEA*** or MDEA + MDA
MDA
Benzoylecgonine benzoylecgonine
Cocaine cocaine + benzoylecgonine or cocaine 
THC THC or THC+THCCOOH
Illicit opiates
6-acetylmorphine or 6-AM + codeine or 6-AM + morphine or 6-AM + codeine + 
morphine or (morphine + codeine and morphine>= codeine)
Medicinal drugs Benzodiazepines 
and Z-drugs
diazepam or diazepam + nordiazepam or diazepam + oxazepam or diazepam + 
nordiazepam + oxazepam
nordiazepam or nordiazepam + oxazepam
oxazepam
lorazepam
alprazolam
flunitrazepam or flunitrazepam + 7-aminoflunitrazepam
clonazepam or clonazepam + 7-aminoclonazepam
zolpidem
zopiclone
Medicinal morphine
opioids codeine or (codeine + morphine and codeine> morphine)
methadone
tramadol
Various Alcohol-drugs all combinations
combinations Multiple drugs all combinations
*Methylenedioxy-methylamphetamine (ecstasy)
** Methylenedioxyamphetamine (ecstasy)
***Methylenedioxyethylamphetamine
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Table 7
Variables in the odds ratio calculations.
Variable Number 
of 
categories
Categories
Age 4 18-24 years of age
25-34 years of age
35-49 years of age
50+ years of age
Gender 2 Male
Female
Country 6 Belgium 
Denmark 
Finland 
Italy 
Lithuania 
The Netherlands 
Alcohol 5 <0.10 g/L (reference group)
0.10-0.49 g/L
0.50-0.79 g/L
0.80-1.19 g/L
1.20+ g/L
Drugs
- Amphetamines
- Benzoylegonine
- Cocaine
- Cannabis
- Illicit opiates
- Benzodiazepines and Z-
drugs
- Medicinal opioids
- Alcohol-drug(s)
- Multiple drugs
2 Concentration below cut-off (i.e. negative, reference 
group)
Positive (concentration above or equal to cut-off): 
– positive for one drug: positive for one drug group only
– positive for alcohol-drug(s): positive for alcohol plus 
one or more drugs
– positive for multiple drugs: positive for more than one 
drug, but not for alcohol
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Table 8
Odds ratios for severe driver injury by driving with psychoactive substances. Odds ratios in brackets are not 
significantly different from one (P<0.05).
Substance N Crude OR 95% C.I. Adjusted** OR 95% C.I.
controls/cases*
Negative (reference) 11073/1177 1.00 1.00
All alcohol concentrations 557/345 7.71 6.61-8.99 9.79 8.18-11.72
    0.1 g/L ≤ alcohol < 0.5 g/L 368/32 (1.07) 0.74-1.55 (1.30) 0.88-1.94
    0.5 g/L ≤ alcohol < 0.8 g/L 90/30 4.03 2.62-6.20 4.18 2.58-6.77
    0.8 g/L ≤alcohol < 1.2 g/L 42/44 14.27 8.91-22.84 16.48 9.64-28.18
    Alcohol ≥ 1.2 g/L 57/239 54.45 39.00-76.02 77.76 54.11-111.74
All illicit drugs 201/57 2.89 2.13-3.91 2.68 1.88-3.82
    Amphetamine 17/15 9.65 4.63-20.11 14.15 5.82-34.42
    Benzoylecgonine  20/9 4.91 2.17-11.12 3.88 1.41-10.68
    Cocaine  18/7 2.83 1.21-6.64 (1.65) 0.66-4.16
    Cannabis 138/24 1.84 1.18-2.87 1.91 1.15-3.17
    Illicit opiates  8/2 (2.40) 0.50-11.45 (1.18) 0.23-5.99
All medicines 215/101 3.59 2.84-4.55 3.60 2.74-4.74
    Benzodiazepines and Z-
drugs 142/34 1.72 1.19-2.50 1.77 1.16-2.69
    Medicinal opioids 73/67 8.00 5.73-11.18 7.37 4.99-10.88
All alcohol-drug 
combinations 40/91 32.74 21.16-50.66 39.15 24.21-63.31
All multiple drug 
combinations 53/50 8.67 5.85-12.85 7.02 4.38-11.24
* Due to sampling skewness, negative samples and samples positive for alcohol or alcohol-drugs from 
Finland and Italy were excluded from the calculations of OR for alcohol and alcohol-drugs.
** Adjusted for age, gender and country.
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Table 9
Odds ratios for severe driver injury when driving positive for psychoactive substances by age and gender
categories. Odds ratios in brackets are not significantly different from one (P<0.05).
Substance Effect Adjusted* OR 95% C.I.
All alcohol concentrations Gender Male vs. female 0.67 0.59-0.76
Age 18-24 vs. 50+ 5.83 4.87-6.98
25-34 vs. 50+ 2.38 1.99-2.84
35-49 vs. 50+ 1.34 1.13-1.59
Amphetamine Gender Male vs. female 0.65 0.58-0.74
Age 18-24 vs. 50+ 2.93 2.49-3.46
25-34 vs. 50+ 1.32 1.12-1.55
35-49 vs. 50+ (0.92) 0.79-1.07
Benzoylecgonine Gender Male vs. female 0.65 0.58-0.73
Age 18-24 vs. 50+ 2.91 2.47-3.43
25-34 vs. 50+ 1.32 1.12-1.55
35-49 vs. 50+ (0.93) 0.80-1.08
Cocaine Gender Male vs. female 0.65 0.58-0.73
Age 18-24 vs. 50+ 2.94 2.50-3.47
25-34 vs. 50+ 1.31 1.11-1.54
35-49 vs. 50+ (0.92) 0.79-1.07
Cannabis Gender Male vs. female 0.65 0.58-0.74
Age 18-24 vs. 50+ 2.96 2.51-3.49
25-34 vs. 50+ 1.33 1.13-1.56
35-49 vs. 50+ (0.92) 0.79-1.07
Illicit opiates Gender Male vs. female 0.65 0.58-0.73
Age 18-24 vs. 50+ 2.95 2.50-3.47
25-34 vs. 50+ 1.31 1.12-1.55
35-49 vs. 50+ (0.92) 0.79-1.08
Benzodiazepines and Z-drugs Gender Male vs. female 0.65 0.58-0.74
Age 18-24 vs. 50+ 2.88 2.45-3.39
25-34 vs. 50+ 1.32 1.12-1.55
35-49 vs. 50+ (0.92) 0.80-1.08
Medicinal opioids Gender Male vs. female 0.66 0.59-0.74
Age 18-24 vs. 50+ 2.98 2.53-3.51
25-34 vs. 50+ 1.33 1.14-1.57
35-49 vs. 50+ (0.94) 0.80-1.09
All alcohol-drug combinations Gender Male vs. female 0.63 0.55-0.72
Age 18-24 vs. 50+ 5.32 4.40-6.43
25-34 vs. 50+ 2.04 1.69-2.47
35-49 vs. 50+ 1.24 1.04-1.49
All multiple drug combinations Gender Male vs. female 0.65 0.58-0.74
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Age 18-24 vs. 50+ 2.92 2.48-3.44
25-34 vs. 50+ 1.34 1.14-1.57
35-49 vs. 50+ (0.93) 0.80-1.09
*Adjusted for age, gender and country. Country not shown for reasons of brevity. 
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Highlights
We estimated risk of serious road accident injury when driving under the influence
Risk of driving with alcohol and other drugs was estimated in a case-control design
Highest risk was associated with driving with high concentrations of alcohol
Other high-risk groups were amphetamine and combinations of alcohol and other drugs
Estimated risks were negatively correlated with age and higher for women than for men
